1Atkins MB, Bukowski RM, Escudier B J, et al. Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference [ J 3. Cancer,2009,115 ( Suppl 10) :2247 - 2251.
2Uchida K, Miyao N, Masumori N, et al. Recurrence of renal eel1 carcinoma more than 5 years after nephrectomy [ J]. Int J Urol,2002,9( 1 ) : 19 - 23.
4Waldmann TA. The biology of interleukin-2 and interleukin-15 : implications for cancer therapy and vaccine design [ J ]. Nat Rev Immunol, 2006,6 ( 8 ) : 595 -601.
5Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma wtlo received high-dose recombinant interleukin-2 therapy [ J ]. J Clin Oncol, 1995, 13 ( 3 ) : 688 - 696.
6Geertsen PF, Gore ME, Negrier S, et al. Safety and efficacy of subcutaneous and continuous intravenous itffusion rlL-2 in patients with metastatic renal cell carcinoma [ J ]. Br J Cancer, 2004-, 90 (6) : 1156 - 1162.
7Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa- 2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunoth6rapie [J]. N Engl J Med, 1998,338 (18) :1272 - 1278.
8Yang JC, Sherry RM, Stienberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer[J]. J Clin Oncol,2003,21 (16) :3127 - 3132.
9McDermott DF, Regan MM, Clark JI,et al. A randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinomar [ J]. J Clin Oncol,2005, 23(1) :133 - 141.
10Negrier S, Perol D, Ravaud C, et al. Medroxyprogeste- rone,interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results from a randomized controlled trial [ J ]. Cancer, 2007, 110 ( 11 ) :2468 -2477.
同被引文献16
1Pitino A, Squillaci S, Spairani C, et al. Primary synovial sarcoma of the kidney. A case report with pathologic appraisal investigation and literature review. Pathologica, 2011, 103 (5) : 271.
2Negrier S, Maral J, Drevon M, et al. Long - term follow - up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin -2 in Europe [ J ]. Cancer J Sci Am.2000, 6 (1) : S93.
3Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin -2, recombinant human interferon alfa - 2a, or both in metastatic renal - cell carcinoma. Groupe Francais dlmmunotherapie [J]. N Engl J Med, 1998, 18 (338) : 1272.
4Bukowski R M Cytokine therapy for metastatic renal cell carcinoma [ J ]. Semin Urol Oncol, 2001, 19 (2): 148.
5Coppin C, Porzsoh F. Immunotherapy for advanced renal cell cancer [ J]. Cochrane Database Syst Rev, 2005, (1) : 1425.
6Fyfe G, isher RI , Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carinoma who received high - dose recombinant interleukin - 2 therapy [ J ]. J Clin Oncol, 1995, (13): 668.
7Fisher RI, Rosenberg SA, Fisher RI, et al. Long - term survival update for high - dose recombi- nant interleukin -2 in patients with renal cell carcinoma [J]. Cancer J Sci Am, 2000, 6: 55.
8Mozter ILl, Agarwal N, Beard C, et al. NCCN clinical practice guidelines in oncology: non - Hodgkin~ lymphomas [J]. J Natl Canl Netw, 2010, 8 (3) : 288.
9Walsh P C, Retik A B, Vaugh E D, et al. Campbells urology (8th ed) [Z]. 2002. 2672.
10Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell cancer [ Z ]. 2006. 1.
